Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center
GLIX1, a TET2 activator ,  is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma  and other cancers Â
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -
Management to Hold Conference Call at 8:30 a.m. EDT
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -
Management to Hold Conference Call at 8:30 a.m. EST
Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers)
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only -
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 - - Provides updated and extended...
Management to Hold Conference Call at 8:30 a.m. EDT